Y. Tamura < Y. Tanaka < Y. Taoufik

Facettes : Author.f AffPays.f AffRegion.f AffVille.f AffOrg.f KwdFr.f Mesh.f MeshFr.f Teeft.f

List of bibliographic references indexed by Y. Tanaka

Number of relevant bibliographic references: 17.

Ident.	Authors (with country if any)	Title
001F03 (2015)	C. Takai ; I. Matsumoto ; A. Inoue ; N. Umeda ; Y. Tanaka ; Y. Kurashima ; Y. Wada [Japon] ; I. Narita [Japon] ; T. Sumida	Specific overexpression of tumour necrosis factor-α-induced protein (TNFAIP)9 in CD14(+) CD16(-) monocytes in patients with rheumatoid arthritis: comparative analysis with TNFAIP3.
002A43 (2013)	H. Yamanaka ; M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu [Japon] ; S. Takei ; T. Takeuchi [Japon] ; Y. Tanaka ; Y. Sano [Japon] ; T. Koike [Japon]	THU0092 The advantage of early intervention by tocilizumab for rheumatoid arthritis - full analysis of all-case postmarketing surveillance in 7,901 patients in japan
002B51 (2013)	T. Takeuchi [Japon] ; Y. Tanaka ; K. Amano ; J. Kikuchi [Japon] ; E. Tanaka [Japon] ; S. Hirata ; H. Nagasawa ; H. Yasuoka [Japon] ; H. Yamanaka [Japon]	SAT0140 Effectiveness of Abatacept Against Rheumatoid Arthritis in Daily Clinical Practice - Orbit Study
002B65 (2013)	M. Harigai ; S. Inokuma [Japon] ; N. Ishiguro ; J. Ryu ; T. Takeuchi [Japon] ; S. Takei ; Y. Tanaka ; H. Yamanaka ; Y. Sano [Japon] ; H. Yaguramaki [Japon] ; T. Koike [Japon]	SAT0120 Characteristics Associated with Better Effectiveness and Safety in Rheumatoid Arthritis Patients Treated with Intravenous Tocilizumab: Results from Full Analysis of All-Patient Postmarketing Surveillance in Japan
002C13 (2013)	S. Hirata [Japon] ; W. Li [États-Unis] ; N. A. Defranoux [États-Unis] ; R. Bolce [États-Unis] ; D. J. Haney [États-Unis] ; E. H. Sasso [États-Unis] ; S. Kubo [Japon] ; S. Fukuyo [Japon] ; Y. Mizuno [Japon] ; K. Yamaoka [Japon] ; K. Saito [Japon] ; Y. Tanaka [Japon]	SAT0012 A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score is Associated with Radiographic Outcomes in RA Patients Treated with TNF Inhibitors
002D30 (2013)	T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. Mimori	OP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study)
002D99 (2013)	K. Saito [Japon] ; K. Hanami [Japon] ; S. Hirata [Japon] ; S. Kubo [Japon] ; M. Nawata [Japon] ; K. Yamaoka [Japon] ; S. Nakayamada [Japon] ; K. Nakano [Japon] ; Y. Tanaka [Japon]	FRI0251 Comparison of lipid profile including high molecular weight adiponectin (HMW-AN) after treatment with three different biologics in the patients with bio-naïve rheumatoid arthritis (RA)
002E53 (2013)	K. Hanami [Japon] ; K. Saito [Japon] ; H. Tasaka [Japon] ; Y. Tanaka [Japon]	FRI0190 CDAI is a predictor of physical function and bone destruction at week 52 in RA patients
002E67 (2013)	Y. Tanaka ; M. Harigai ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Yamamoto [Japon] ; M. Kanazawa ; Y. Murakami ; T. Yoshinari [Japon] ; D. Baker [États-Unis] ; N. Miyasaka ; T. Koike [Japon]	FRI0177 52-week results of clinical, radiographic and pharmacokinetic assessments: Golimumab, a human anti-TNF monoclonal antibody, administered subcutaneously every four weeks in patients with active rheumatoid arthritis despite methotrexate therapy
002F13 (2013)	K. Hanami [Japon] ; S. Hirata [Japon] ; H. Tasaka [Japon] ; W. Li [États-Unis] ; R. Bolce [États-Unis] ; E. H. Sasso [États-Unis] ; N. A. Defranoux [États-Unis] ; K. Yamaoka [Japon] ; K. Saito [Japon] ; Y. Tanaka [Japon]	FRI0066 Behavior of the multi-biomarker disease activity (vectra da algorithm) score and components in patients with rheumatoid arthritis treated with tocilizumab
002F15 (2013)	S. Fukuyo [Japon] ; K. Yamaoka [Japon] ; K. Sonomoto [Japon] ; K. Oshita [Japon] ; Y. Okada [Japon] ; K. Saito [Japon] ; Y. Tanaka [Japon]	FRI0055 Ectopic calcification is mediated by inflammatory cytokines enhancing differentiation of adipose-derived stem cells into osteoblasts
003070 (2013)	Y. Tanaka ; T. Abe ; T. Takeuchi ; A. Yamamoto ; N. Miyasaka [Japon]	AB0587 Safety and efficacy of abatacept(ABA) demonstrated in patients with rheumatoid arthritis(RA); 4-year data from phase III open-label, multicenter, long-term extension trial
003071 (2013)	Y. Tanaka ; T. Takeuchi [Japon] ; K. Amano ; E. Sato [Japon] ; M. Nawata ; H. Nagasawa ; D. Hoshi [Japon] ; K. Saito ; S. Fukuyo ; K. Hanami ; H. Kameda [Japon] ; T. Kurasawa ; Y. Kaneko [Japon] ; H. Yamanaka [Japon]	AB0586 104-weeks assessments of clinical and structural remission in rheumatoid arthritis patients with tocilizumab from the reaction study
003110 (2013)	K. Hanami [Japon] ; K. Saito [Japon] ; H. Tasaka [Japon] ; Y. Tanaka [Japon]	AB0546 Clinical and functional remission based on newly defined ACR/EULAR remission criteria achieved with tocilizumab in patients with rheumatoid arthritis
003239 (2013)	Y. Tanaka ; K. Yamamoto [Japon] ; T. Takeuchi ; H. Yamanaka [Japon] ; N. Ishiguro ; K. Eguchi ; A. Watanabe [Japon] ; H. Origasa ; T. Okamoto ; T. Shoji ; N. Miyasaka [Japon] ; T. Koike [Japon]	AB0294 Long-term comprehensive disease control with certolizumab pegol regardless of concomitant dmards: results from the japanese cohort
003564 (2012)	Y. Tanaka [Japon] ; Y. Maeshima [Japon] ; K. Yamaoka [Japon]	In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
003631 (2012)	P. P. Tak [Pays-Bas] ; P. J. Mease [États-Unis] ; M. C. Genovese [États-Unis] ; J. Kremer [États-Unis] ; B. Haraoui [Canada] ; Y. Tanaka [Japon] ; C. O. Bingham Iii [États-Unis] ; A. Ashrafzadeh [États-Unis] ; H. Travers [Royaume-Uni] ; S. Safa-Leathers [Royaume-Uni] ; S. Kumar [Royaume-Uni] ; W. Dummer [États-Unis]	Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i -k "Y. Tanaka" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i  \
                -Sk "Y. Tanaka" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Author.i
   |clé=    Y. Tanaka
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021